Galapagos presents superior potentiator series for CF
(Thomson Reuters ONE) -
* Novel proprietary series to start clinical trials end of 2014
* Superior CFTR channel opening shown in cells from CF patients
* Favorable ADME/PK profile and selectivity
Mechelen, Belgium; 17 October 2013 - Galapagos NV (Euronext: GLPG) has developed
a series of novel potentiators in its cystic fibrosis program. The data will be
presented at the North American Cystic Fibrosis Conference taking place from
17 - 19 October in Salt Lake City, Utah.
In its CF research program, Galapagos developed novel potentiator series that
are highly potent and that show superior opening of the defective CFTR channel
in comparison to Kalydeco(®). This was shown in assays of cells that carry a
CFTR class II, III or IV mutation. Furthermore, the superior channel opening
was confirmed in primary cells from F508del and G551D patients. In addition to
its efficacy, the Galapagos series show good metabolic stability and
permeability and favorable PK profiles. In comparison to Kalydeco(®), the new
potentiators have a superior in vitro safety profile, including a clean CYP
profile and high selectivity. These results encourage Galapagos to nominate a
pre-clinical candidate from this series at the end of this year, with the first
clinical trials starting at the end of 2014. Galapagos has pending patents on
these novel potentiators.
Galapagos initiated its research in CF in 2005 as part of a collaboration with
the Cystic Fibrosis Foundation. In 2010 Galapagos decided to pursue CF as the
first orphan disease in which the company is attempting to discover, develop and
launch its own medicines. In September 2013 Galapagos signed an agreement with
AbbVie where they will work collaboratively to develop and commercialize oral
drugs that address the main mutations in CF patients, including F508del and
G551D. Galapagos will present its novel potentiators at a poster session
(abstract #41) at NACFC on 17 October at 11:50 am and 18 October at 4 pm and is
available online at www.glpg.com.
About Cystic Fibrosis
Cystic fibrosis (CF) is a hereditary disease of the entire body which leads to
severe disability and early death in many cases. Symptoms include frequent lung
infections, sinus infections, poor growth, and diarrhea. The cause is a defect
in gene which encodes for cystic fibrosis transmembrane conductance regulator
(CFTR), a protein which regulates components of sweat, mucus, and digestive
juices. CF affects approximately 70,000 people worldwide. Patient symptoms are
treated with antibiotics and other medicines. There currently is no cure for
the disease, and the predicted median age of survival is in the late 30s. For
more information about cystic fibrosis, visitwww.cff.org.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with a large pipeline of five Phase 2 (two led by GSK), one Phase 1, six pre-
clinical, and 20 discovery small-molecule and antibody programs in cystic
fibrosis, inflammation, antibiotics, metabolic disease, and other indications.
AbbVie and Galapagos signed an agreement in CF where they work collaboratively
to develop and commercialize oral drugs that address two mutations in the CFTR
gene, the G551D and F508del mutation. In the field of inflammation, AbbVie and
Galapagos signed a worldwide license agreement whereby AbbVie will be
responsible for further development and commercialization of GLPG0634 after
Phase 2B. GLPG0634 is an orally-available, selective inhibitor of JAK1 for the
treatment of rheumatoid arthritis and potentially other inflammatory diseases,
currently in Phase 2B studies in RA and about to enter Phase 2 studies in
Crohn's disease. Galapagos has another selective JAK1 inhibitor in Phase 2 in
lupus and psoriasis, GSK2586184 (formerly GLPG0778, in-licensed by
GlaxoSmithKline in 2012). GLPG0974 is the first inhibitor of FFA2 to be
evaluated clinically for the treatment of IBD; this program is currently in a
Proof-of-Concept Phase 2 study. GLPG1205 is a first-in-class molecule that
targets inflammatory disorders and is currently in a First-in-Human Phase 1
study.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and
Fidelta, has around 800 employees and operates facilities in five countries,
with global headquarters in Mechelen, Belgium. Further information at:
www.glpg.com
Contact
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir(at)glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
Galapagos presents superior potentiator series for CF:
http://hugin.info/133350/R/1736243/581827.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
[HUG#1736243]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Two More Advertising Agencies Come To WWW.PAZOO.COM And All Coding And Technology Changes Are Now CompleteDatum: 17.10.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 306599
Anzahl Zeichen: 7080
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 214 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos presents superior potentiator series for CF"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
